Phase I Trial to Investigate Safety and Tolerability Profile and Pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours
Latest Information Update: 31 Jul 2024
At a glance
- Drugs HS 10241 (Primary)
- Indications Carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Jiangsu Hansoh Pharmaceutical
- 02 Dec 2016 New trial record